Related Experiment Video
Updated: May 9, 2026

Assessment of Global DNA Double-Strand End Resection using BrdU-DNA Labeling coupled with Cell Cycle Discrimination Imaging
Published on: April 28, 2021
Targeting DNA double-strand break signalling and repair: recent advances in cancer therapy
Daniela Hühn1, Hella A Bolck, Alessandro A Sartori
1Institute of Molecular Cancer Research, University of Zurich, Switzerland.
Abstract:
Genomic instability, a hallmark of almost all human cancers, drives both carcinogenesis and resistance to therapeutic interventions. Pivotal to the ability of a cell to maintain genome integrity are mechanisms that signal and repair deoxyribonucleic acid (DNA) double-strand breaks (DSBs), one of the most deleterious lesions induced by ionising radiation and various DNA-damaging chemicals. On the other hand, many current therapeutic regimens that effectively kill cancer cells are based on the induction of excessive DSBs. However, these drugs often lack selectivity for tumour cells, which results in severe side effects for the patients, thus compromising their therapeutic potential. Therefore, the development of novel tumour-specific treatment strategies is required. Unlike normal cells, however, cancer cells are often characterised by abnormalities in the DNA damage response including defects in cell cycle checkpoints and/or DNA repair, rendering them particularly sensitive to the induction of DSBs. Therefore, new anticancer agents designed to exploit these vulnerabilities are becoming promising drugs for enhancing the specificity and efficacy of future cancer therapies. Here, we summarise the latest preclinical and clinical developments in cancer therapy based on the current knowledge of DSB signalling and repair, with a special focus on the combination of small molecule inhibitors with synthetic lethality approaches.
Insights
Genomic instability fuels cancer. Exploiting cancer cells
Area of Science:
- Molecular Biology
- Oncology
- Genetics
Background:
- Genomic instability is a key characteristic of human cancers, contributing to tumor development and treatment resistance.
- DNA double-strand breaks (DSBs) are critical DNA lesions that must be signaled and repaired to maintain genome integrity.
Purpose of the Study:
- To review recent advances in cancer therapy targeting DNA double-strand break (DSB) signaling and repair.
- To explore novel strategies that exploit cancer cell vulnerabilities for enhanced treatment specificity and efficacy.
Main Methods:
- Review of preclinical and clinical studies on DSB repair mechanisms in cancer.
- Focus on combining small molecule inhibitors with synthetic lethality approaches.
- Analysis of DNA damage response pathways and cell cycle checkpoint functions in cancer cells.
Main Results:
- Cancer cells often exhibit defects in DNA damage response, making them uniquely sensitive to DSB induction.
- Targeting these vulnerabilities with novel anticancer agents shows promise for improving cancer therapy.
- Combination therapies, particularly involving small molecule inhibitors and synthetic lethality, are emerging as effective strategies.
Conclusions:
- Exploiting cancer-specific defects in DSB repair offers a promising avenue for developing targeted cancer therapies.
- The combination of small molecule inhibitors with synthetic lethality approaches holds significant potential for increasing treatment efficacy and reducing side effects.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
DNA Damage can Stall the Cell Cycle
DNA Damage Can Stall the Cell Cycle
Fixing Double-strand Breaks
Fixing Double-strand Breaks

